The area of male contraceptive development is rapidly advancing with several candidates in advanced clinical trials. Concurrently, research scientists continue to look for novel male directed contraceptives that are efficacious, safe and acceptable in order to expand contraceptive options for men and promote shared responsibility for pregnancy prevention.
The Target Product Profiles (TPP) for Male Contraceptive Methods provide important information on key parameters and values to be used for research and development of high quality, evidence-based, effective, safe, acceptable and affordable male contraceptives. Male contraceptive target TPPs are crucial in guiding and aligning male contraceptive product developers, regulatory authorities, procurement agencies and other key stakeholders on the optimal characteristics of novel MCs including the minimal essential characteristics for their usability, while taking cognizance of end user preferences and public health priorities in sexual and reproductive health.
The World Health Organization (WHO) and HRP (the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction) have drafted the first consolidated male contraceptive TPP covering three groups of male contraceptive methods. These include TPPs for male contraceptives targeting spermatogenesis, TPPs for male contraceptives targeting suppression of sperm function, and TPP for Vas deferens occlusion methods.
The document is undergoing an external public review before it is finalized, published and disseminated. Respondents may review one, two or all three of the TPPs. Feedback for each TPP should be provided separately using the relevant form provided.
The link to the survey questionnaire for giving your comments or reviews may be found here.
The public review will close on 3 April 2026.
Related links: Target product profiles for Male contraceptive methods